Cell Source, Inc. (CLCS)

OTCMKTS: CLCS · Delayed Price · USD
0.311
-0.269 (-46.38%)
Mar 28, 2024, 3:25 PM EDT - Market closed

Company Description

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance.

The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses.

Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases.

Cell Source, Inc. was incorporated in 2012 and is headquartered in New York, New York.

Cell Source, Inc.
Country NY
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Itamar Shimrat

Contact Details

Address:
57 West 57th Street, Suite 400
New York, New York 10019
United States
Phone 646-612-7554
Website cell-source.com

Stock Details

Ticker Symbol CLCS
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001569340
CUSIP Number 15114L104
ISIN Number US15114L1044
Employer ID 32-0379665
SIC Code 2834

Key Executives

Name Position
Dr. Dennis M. Brown B.Sc., M.A., Ph.D. Executive Chairman
Itamar Shimrat Chief Executive Officer, President and Chief Financial Officer

Latest SEC Filings

Date Type Title
Nov 9, 2023 10-Q Quarterly Report
Oct 6, 2023 D Notice of Exempt Offering of Securities
Sep 19, 2023 10-Q Quarterly Report
Aug 23, 2023 10-Q Quarterly Report
Aug 15, 2023 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Aug 8, 2023 10-K Annual Report
May 16, 2023 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Mar 31, 2023 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Dec 8, 2022 10-Q Quarterly Report
Dec 2, 2022 10-Q Quarterly Report